KeyBanc analyst Steve Dechert initiated coverage of Zoetis (ZTS) with a Sector Weight rating. The firm is citing continued headwinds from the launch of the company’s OA pain mAb products and increased competition in key franchises, the analyst tells investors in a research note. While KeyBanc recognizes Zoetis’s history of excellence in developing innovative products, the firm sees shares as being fairly valued while it awaits new innovative product launches.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZTS: